Dr. Lior Shaltiel reports

REGENERATION AND REINNERVATION OF SPINAL CORD IN RATS TREATED WITH NUREXONE'S INTRANASAL EXOPTEN

Nurexone Biologic Inc. has released positive imaging results from an internal preclinical study of its investigational drug ExoPTEN. The image analysis and measurements confirmed successful nerve regeneration following traumatic transection of the spinal cord in rats. These imaging results align with previous results showing a remarkable recovery of motor function in 75 per cent of paralyzed rats suffering from spinal cord injuries and treated with the new therapy.

During a recent internal preclinical trial, the company's ExoPTEN drug caused 75 per cent of rats to regain hind limb reflex, some motor function and sensory control. Subsequently, the spinal cords of rats from the study were subjected to advanced diffusion tensor imaging (DTI) to assess the structural integrity of the spinal cord. Nurexone's DTI analysis yielded representative observations for different rat groups as follows:

• Intranasal ExoPTEN with recovered motor function -- reinnervation, indicating a restoration of nerve supply to the spinal cord below the transection;
• Control group -- atrophied and deinnervated spinal cord below the transection;
• A healthy spinal cord, without trauma, is included as a reference for comparison.

DTI was performed using conventional magnetic resonance imaging (MRI) and diffusion tensor imaging techniques. Furthermore, fractional anisotropy (FA) measurements were used for a quantitative assessment of tissue integrity. The results showed higher FA values indicating reduced tissue microstructural damage in the caudal region of the ExoPTEN-treated rats compared with the control SCI group. It is important to note that the nerves below the lesion site presented better survival and less degeneration, which is one of the common pathophysiological conditions after injury.

ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI) administrated intranasally and yielding neuron regeneration and rewiring in traumatically damaged spinal cords. The drug is being developed using Nurexone's proprietary ExoTherapy platform for producing and loading exosomes with pharmaceutical cargo targeting central nervous system injuries.

"We are delighted to receive promising results from this study, which demonstrated reinnervation as a result of our ExoPTEN product," said Dr. Lior Shaltiel, chief executive officer. "Moreover, it validates the functional recovery we observed with non-invasive administration of our investigational ExoPTEN drug. We are eager to advance our research and clinical trials to translate these results to the millions of human patients in need."

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.

ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. Nurexone is translating the treatment to humans, and the company holds an exclusive worldwide licence from the Technion and Tel Aviv University for the development and commercialization of the technology.

We seek Safe Harbor.